CB1 cannabinoid receptor-mediated modulation of food intake in mice
Jenny L. Wiley,James J. Burston,Darnica C Leggett,Olga O. Alekseeva,Raj K. Razdan,Anu Mahadevan,Billy R. Martin +6 more
Reads0
Chats0
TLDR
The results strongly suggest that CB1 receptors may play a role in regulation of feeding behavior and that SR141716A may affect the actions of endogenous cannabinoids in regulating appetite.Abstract:
1 Marijuana's appetite-increasing effects have long been known. Recent research suggests that the CB(1) cannabinoid receptor antagonist SR141716A may suppress appetite. This study represents a further, systematic investigation of the role of CB(1) cannabinoid receptors in the pharmacological effects of cannabinoids on food intake. 2 Mice were food-restricted for 24 h and then allowed access to their regular rodent chow for 1 h. Whereas the CB(1) antagonist SR141716A dose-dependently decreased food consumption at doses that did not affect motor activity, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) increased food consumption at doses that had no effect on motor activity. O-3259 and O-3257, structural analogs of SR141716A, produced effects similar to those of the parent compound. 3 Amphetamine (a known anorectic) and diazepam (a benzodiazepine and CNS depressant) decreased food consumption, but only at doses that also increased or decreased motor activity, respectively. The CB(2) cannabinoid receptor antagonist SR144528 and the nonpsychoactive cannabinoid cannabidiol did not affect food intake nor activity. 4 SR141716A decreased feeding in wild-type mice, but lacked pharmacological activity in CB(1) knockout mice; however, basal food intake was lower in CB(1) knockout mice. Amphetamine decreased feeding in both mouse genotypes. 5 These results suggest that SR141716A may affect the actions of endogenous cannabinoids in regulating appetite or that it may have effects of its own aside from antagonism of cannabinoid effects (e.g., decreased feeding behavior and locomotor stimulation). In either case, these results strongly suggest that CB(1) receptors may play a role in regulation of feeding behavior.read more
Citations
More filters
Journal ArticleDOI
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
TL;DR: A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.
Journal ArticleDOI
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
TL;DR: This review focuses on the manner with which three of these compounds, (−)‐trans‐Δ 9‐tetrahydrocannabinol (Δ9‐THC), (−]‐cannabidiol (CBD) and (−)-trans‐ Δ9‐TetrahYDrocannabivarin (Γ‐THCV), interact with cannabinoid CB1 and CB2 receptors.
Journal ArticleDOI
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen,Pernelle Kruse Kristensen,Pernelle Kruse Kristensen,Else Marie Bartels,Henning Bliddal,Arne Astrup +5 more
TL;DR: The findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials.
Journal ArticleDOI
Safety and side effects of cannabidiol, a Cannabis sativa constituent.
Mateus M. Bergamaschi,Regina Helena Costa Queiroz,Antonio Waldo Zuardi,José Alexandre de Souza Crippa +3 more
TL;DR: In vivo and in vitro reports of CBD administration across a wide range of concentrations suggest controlled CBD may be safe in humans and animals, but further studies are needed to clarify reported in vitro and in vivo side effects.
Journal ArticleDOI
Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission.
TL;DR: The results shed new light in further understanding the biphasic effects of cannabinoids at the molecular level and pave the way for the development of novel anxiolytic cannabinoid drugs, which may have favorable effect profiles targeting the CB1 receptor on glutamatergic terminals.
References
More filters
Journal ArticleDOI
Actual causes of death in the United States.
J M McGinnis,W H Foege +1 more
TL;DR: The most prominent contributors to mortality in the United States in 1990 were tobacco, diet and activity patterns, alcohol, microbial agents, toxic agents, firearms, sexual behavior, motor vehicles, and illicit use of drugs.
Journal ArticleDOI
Actual causes of death in the United States, 2000.
TL;DR: These analyses show that smoking remains the leading cause of mortality in the United States, however, poor diet and physical inactivity may soon overtake tobacco as the lead cause of death.
Journal ArticleDOI
Actual Causes of Death in the United States
TL;DR: The article entitled "Actual Causes of Death in the United States" was misleading in a number of ways, and misleadingly suggests that heart disease and cancers are not leading causes of death.
Journal ArticleDOI
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Murielle Rinaldi-Carmona,Francis Barth,Michel Heaulme,David Shire,Bernard Calandra,Christian Congy,Serge Martinez,Jeanne Maruani,Gervais Neliat,Daniel Caput,P. Ferrara,Philippe Soubrie,J. C. Breliere,Gérard Le Fur +13 more
TL;DR: SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor and should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.
Related Papers (5)
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
Daniela Cota,Giovanni Marsicano,Matthias H. Tschöp,Yvonne Grübler,Cornelia Flachskamm,M. I. Schubert,Dorothee P. Auer,Alexander Yassouridis,Christa Thöne-Reineke,Sylvia Ortmann,Federica Tomassoni,Cristina Cervino,Enzo Nisoli,Astrid C E Linthorst,Renato Pasquali,Beat Lutz,Günter K. Stalla,Uberto Pagotto +17 more